Literature DB >> 2694209

The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature.

J M Esdaile1, C Levinton, W Federgreen, J P Hayslett, M Kashgarian.   

Abstract

The prognostic markers in 87 consecutive patients with lupus nephritis who underwent renal biopsy are reported for five clinically relevant long-term outcomes--renal insufficiency, renal failure, death due to renal systemic lupus erythematosus, death due to non-renal SLE and death due to SLE, both renal and non-renal. We have demonstrated that a number of previously neglected or rarely studied predictors were important prognostic markers. These included the duration of renal disease before biopsy, overall severity of SLE, as well as the presence of vasculitis, hypertension or a comorbid ailment. Furthermore, the study confirms the predictive importance of serum creatinine, 24-h urinary excretion of protein, C3, and of the activity and chronicity indices on biopsy. However, overall a simple measure of tubulointerstitial disease was the best predictor obtained from biopsy. Prognostic models based on clinical data alone were developed for each of the five outcomes. The models amplify our clinical understanding of lupus nephritis. Markers of renal severity were most important in predicting renal outcomes such as renal insufficiency and renal failure. Prognostic factors less directly related to renal disease (comorbidity and vasculitis) were important predictors of fatality. A marker of immunologic disease activity (C3) was a valuable predictor for many of the outcomes. Thus markers of disease severity reflecting organ damage due to SLE and other comorbid conditions could be combined with markers of immunologic activity to predict a variety of outcomes of relevance to a clinician. When biopsy data obtained by light or electron microscopy were evaluated for their ability to add new predictive information to the clinical models, only a limited value for biopsy was noted. It is likely that this reflected the close correlational relationships between clinical and biopsy variables, the strong clinical models generated, and the inclusion in the clinical models of the previously neglected clinical variables, duration of renal disease before biopsy and the presence of vasculitis or comorbid disease.

Entities:  

Mesh:

Year:  1989        PMID: 2694209

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  36 in total

1.  In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.

Authors:  Anthony Chang; Scott G Henderson; Daniel Brandt; Ni Liu; Riteesha Guttikonda; Christine Hsieh; Natasha Kaverina; Tammy O Utset; Shane M Meehan; Richard J Quigg; Eric Meffre; Marcus R Clark
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

2.  Semiquantitative and semi-automated morphometric evaluation of chronic lesions in renal biopsies.

Authors:  Daniel Abensur Athanazio; Gloria Maria Maranhão Sweet; Carlos Alberto Silva; Washington Luis Conrado dos-Santos
Journal:  Int Urol Nephrol       Date:  2008-11-07       Impact factor: 2.370

Review 3.  The Revisited Classification of GN in SLE at 10 Years: Time to Re-Evaluate Histopathologic Lesions.

Authors:  Suzanne Wilhelmus; Charles E Alpers; H Terence Cook; Franco Ferrario; Agnes B Fogo; Mark Haas; Kensuke Joh; Laure-Hélène Noël; Surya V Seshan; Jan A Bruijn; Ingeborg M Bajema
Journal:  J Am Soc Nephrol       Date:  2015-07-07       Impact factor: 10.121

4.  Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study.

Authors:  Anna Broder; Wenzhu B Mowrey; Hina N Khan; Bojana Jovanovic; Alejandra Londono-Jimenez; Peter Izmirly; Chaim Putterman
Journal:  Semin Arthritis Rheum       Date:  2017-07-14       Impact factor: 5.532

5.  Clinicopathological study of male and female patients with lupus nephritis: a retrospective study.

Authors:  Wei Peng; Yi Tang; Li Tan; Wei Qin
Journal:  Int Urol Nephrol       Date:  2018-01-03       Impact factor: 2.370

6.  Prospective validation of a novel renal activity index of lupus nephritis.

Authors:  G Gulati; M R Bennett; K Abulaban; H Song; X Zhang; Q Ma; S V Brodsky; T Nadasdy; C Haffner; K Wiley; S P Ardoin; P Devarajan; J Ying; B H Rovin; H I Brunner
Journal:  Lupus       Date:  2016-12-19       Impact factor: 2.911

Review 7.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.

Authors:  Marcus R Clark; Kimberly Trotter; Anthony Chang
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

Review 8.  Overview of pathophysiology and treatment of human lupus nephritis.

Authors:  Kimberly Trotter; Marcus R Clark; Vladimir M Liarski
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

9.  Increased excretions of glycosaminoglycans and heparan sulfate in lupus nephritis and rheumatoid arthritis.

Authors:  Ilhan Biçer; Kenan Aksu; Zuhal Parildar; Tijen Tanyalçin; Eker Doğanavşargil; Fatma Z Kutay
Journal:  Rheumatol Int       Date:  2003-03-12       Impact factor: 2.631

10.  Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study.

Authors:  X W Zhang; Chun Li; X X Ma; J X Zhao; Yuan An; Shuang Liu; Yan Li; Z G Li
Journal:  Clin Rheumatol       Date:  2014-04-18       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.